Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Sep 18, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gast...
    PDF
    Sep 18, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gast...
    PDF
    Sep 13, 2017
    Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions PPIs are one of the most commonly prescribed classes of medications in the U.S., with an es...
    PDF
    Sep 7, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gast...
    PDF
    Aug 31, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 31, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastr...
    PDF
    Aug 17, 2017
    RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories          Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, pr...
    PDF
    Aug 10, 2017
    RedHill's U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill's late clinical-stage GI products, if approved, and for the acquisition of additional commercial GI productsThe ERADICATE Hp2 confirmatory Phase III study with TALICIA...
    PDF
    Jul 31, 2017
    The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study To date, over 300 of the planned 410 subjects, have been randomized in the Phase III MAP US study An open-label extension Phase ...
    PDF
    Jul 25, 2017
    RedHill maintains a debt-free balance sheet with $51 million cash1 at the end of the second quarter of 2017  Select recent milestones include: Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. by RedHill's GI-focused sales force with two GI specialty products, Do...
    PDF
    Jul 18, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastr...
    PDF
    Page:
    1
    ... NextLast

    Subscribe to press releases